IMVARIA & Medical Horizons

BERKELEY, Calif. – June 10th, 2025.

IMVARIA, a health tech company pioneering AI-driven digital biomarker solutions, announces a strategic distribution partnership with Medical Horizons, a premier AI-powered medical device distributor based in Florence, Italy. This partnership makes it easier for pulmonologists based in the Middle East and North Africa (MENA) region to have access to breakthrough AI-powered diagnostic tools, including Fibresolve and ScreenDx, which use AI to help guide safe, non-invasive diagnoses of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF).

“We are bringing IMVARIA’s AI innovation to pulmonologists across the MENA region through our new relationship with Medical Horizons,” said Joshua Reicher, MD, Co-founder and CEO of IMVARIA. “Clinicians in the MENA region are among the early adopters of AI for healthcare, and we see a significant opportunity for IMVARIA to broaden our presence strategically in this region of the world. This builds on the success that we have had with FDA authorizations for IMVARIA’s AI tools in the U.S. Our partnership with Medical Horizons affirms our ability to meet the highest medical standards and to take the next step in our geographic expansion.”

Medical Horizons is a trusted distributor of cutting-edge medical technologies, working closely with top-tier companies worldwide to integrate high-level AI solutions into clinical practice. The company’s extensive sales network and expertise in cloud-based healthcare solutions will provide a strong foundation for accelerating the adoption of IMVARIA’s technology among pulmonologists. Medical Horizons has a proven track record of successfully bringing sophisticated AI-based medical solutions to leading healthcare institutions, including installations at renowned centers such as Campus Biomedico Roma, Meyer Labs Florence, Sant’ Andrea Roma, and Gruppo Multimedia Milano.

“The introduction of IMVARIA to the Middle East and North Africa region will give pulmonologists a powerful adjunct tool to help with verifying a diagnosis or ruling out ILD or IPF in a non-invasive manner,” said Guido Osti, CEO at Medical Horizons. “IMVARIA’s AI innovation complements the clinical decision-making that pulmonologists engage in every day. It adds another tool in the pulmonologist’s toolbox, making AI work for them.”

IMVARIA’s Fibresolve received U.S. FDA authorization in early 2024, and ScreenDx received FDA clearance in 2025, after completing rigorous processes to make these technologies useful and reliable for expert clinicians.

“By combining IMVARIA’s AI innovations with Medical Horizons’ extensive market reach, we’ll be able to empower a significant number of pulmonologists in the MENA region to make better diagnoses in these complex lung diseases,” said Michael Muelly, MD, Co-founder and CTO of IMVARIA. “We have eliminated the burden of AI for pulmonologists, while making it accessible for doctors to use as an assistant with patient care. Medical Horizons will play a pivotal role in bringing our unique AI-driven digital biomarker-based solutions to the MENA region medical community.”

About IMVARIA Inc.

IMVARIA is a health tech company pioneering AI-driven solutions that empower clinicians to make accurate diagnoses and prognoses at earlier stages of disease. Founded in 2019 by physician-engineers from Google and Stanford University, the company operates its AI Lab with automated, machine-learning algorithm technology to transform clinical decision-making into data science. IMVARIA is based in Berkeley, CA.

For more information, go to www.imvaria.com.